Intravitreal (IVT) Injectable Market to Reach US$ 26.5 Billion by 2034 | Rising Eye Disorders & Drug Innovations Drive Growth

Rising Adoption of IVT Injectables for Age-Related Macular Degeneration (AMD): Fact.MR Reports

The global intravitreal (IVT) injectable market size is expected to reach US$ 17,565.4 million in 2024 and is projected to witness a CAGR of 4.2% from 2024 to 2034. By 2034, the intravitreal (IVT) injectable demand is anticipated to reach a valuation of US$ 26,526.1 million.

Innovations in medication delivery technologies and the rising incidence of eye diseases are propelling the intravitreal (IVT) injectable market expansion. The aging population and the increasing need for low-risk, efficient treatment solutions are surging the market demand.

The rising emphasis on research and development to bring novel medication formulations is expected to spur market growth. The increasing utilization of combination therapies and the rise of biosimilars present lucrative opportunities for intravitreal (IVT) injectable manufacturers.

Obstacles, including the high expense of intravitreal injections and possible problems, are likely to impede the intravitreal injectable market expansion. The IVT injectable market is anticipated to develop due to regulatory support, rising healthcare spending, and technological advancements.

For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=9541

Key Takeaways from the Market Study:

• The anti-VEGF segment is set to grab a share of 87.6% of the market based on the drug class category.
• In the indication category, the macular degeneration segment is expected to acquire a market share of 31.5%.
• The hospital pharmacies segment in the distribution channel category is expected to grab a market share of 35.6%.
• The United States IVT injectable market is anticipated to surge at a CAGR of 3.3% from 2024 to 2034.
• Canada’s intravitreal injectable market is projected to develop at a CAGR of 4.4% through 2034.
• Mexico’s IVT injectable market is anticipated to surge at a CAGR of 5.2% from 2024 to 2034.
• China’s intravitreal (IVT) injectable market is expected to surge at a CAGR of 6.7% through 2034.
• South Korea’s intravitreal (IVT) injectable industry is anticipated to grow at a CAGR of 6.4% until 2034.
• Japan’s intravitreal (IVT) injectable market is set to exhibit a CAGR of 6.6% through 2034.

Get a Custom Analysis for Targeted Research Solutions: https://www.factmr.com/connectus/sample?flag=S&rep_id=9554

“With the rising cases of retinal illnesses, the demand for intravitreal (IVT) injectables is rising. The market is also growing due to the rising aging populations and biopharmaceutical advancements, creating profitable opportunities for pharmaceutical businesses,” says an analyst at FactMR.

Leading Players Driving Innovation in the Intravitreal (IVT) Injectable Market:

Regeneron Pharmaceuticals, Inc.; Bausch & Lomb; Novartis AG; Allergan; Alimera Sciences; ThromboGenics, Inc.; Bristol-Myers Squibb Company; Other

Competitive Landscape

The market is characterized by the presence of several global intravitreal (IVT) injectable producers. Prominent intravitreal (IVT) injectable vendors in the market use organic and inorganic strategies, such as product releases, partnerships, agreements, etc., to increase their market reach and expand their product portfolios.

Regional Outlook:

The intravitreal (IVT) injectable market in North America has been rapidly evolving due to strict regulatory standards and a proactive stance toward adopting innovative medical therapies.

The robust pharmaceutical industry in Europe stimulates innovation and the development of new therapies for retinal diseases. The Europe IVT injectable market is growing because of the improved accessibility of intravitreal therapies for patients, supported by stable economies and well-established healthcare systems.

Due to the growing geriatric population and increased incidences of retinal illnesses, Asia Pacific is experiencing considerable growth in demand for intravitreal (IVT) injectables. The market is developing in Asia Pacific due to improvements in the region's healthcare system and rising public awareness of eye health issues.Intravitreal (IVT) Injectable Market News:

• In October 2021, Bausch + Lomb and Clearside Biomedical, Inc. launched XIPERE, a suprachoroidal injection of triamcinolone acetonide, which has been approved by the FDA for the treatment of uveitis-associated macular edema.
• Roche published the first ever successful phase II study results in July 2018 of an extended release delivery device for treatment of neovascular age-related macular degeneration (AMD).
• The United States Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals, Inc.'s EYLEA® (aflibercept) Injection in August 2018.

Get Customization on this Report for Specific Research Solutions: https://www.factmr.com/connectus/sample?flag=S&rep_id=9541

More Valuable Insights on Offer:

Fact.MR, in its new offering, presents an unbiased analysis of the global intravitreal (IVT) injectable market, presenting historical data for 2019 to 2023 and forecast statistics for 2024 to 2034.

The study reveals essential insights on the basis of the drug class, indication, distribution channel, and region. By drug class, it includes anti-VEGF, corticosteroids, antibiotics, antivirals, and antifungals. The market is categorized by indication into diabetic retinopathy, macular degeneration, endophthalmitis, retinal vein occlusions, and other conditions. Distribution channels comprise hospital pharmacies, retail pharmacies, drug stores, mail-order pharmacies, and others. Geographically, the market is analyzed across North America, East Asia, South Asia and the Pacific, Western Europe, Eastern Europe, and the Middle East and Africa.

Check out More Related Studies Published by Fact.MR Research:

According to a new industry report released by Fact.MR, the turnover of the global injectable ketamine market is analyzed at US$ 750 million in 2024 and is projected to expand at a double-digit CAGR of 16.4% to achieve a value of US$ 3.42 billion by the end of 2034.

The global sterile injectable drug market size is set to reach a valuation of US$ 611.7 billion in 2024. Sterile injectable drugs are an essential part of the worldwide healthcare sector as they are used for treating life-threatening diseases, including cancer and diabetes, as well as cardiovascular, musculoskeletal, and CNS disorders.

The global injectable drug delivery market is estimated to reach US$ 49,446.0 million in 2024 and is forecast to reach a value of US$ 1,10,998.3 million by 2034, with a projected CAGR of 8.4% from 2024 to 2034.

The global generic injectables market is likely to be valued at US$ 1.02 billion in FY 2022, up from US$ 0.8 billion in 2021. From 2022 to 2032, Generic Injectables sales are poised to flourish at a CAGR of 13.3% to reach a value of US$ 3.6 billion by the end of 2032.

The global injection pen market growth has been forecasted to increase at 7.2% CAGR and reach US$ 93.4 billion by the end of 2034, up from US$ 46.72 billion in 2024.